Aripiprazole + Olanzapine + Risperidone + Quetiapine + Ziprasidone + Aripiprazole + Olanzapine + Risperidone + Quetiapine + Ziprasidone
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia and Schizoaffective Disorder
Conditions
Schizophrenia and Schizoaffective Disorder
Trial Timeline
Dec 1, 2006 → Feb 1, 2008
NCT ID
NCT00347425About Aripiprazole + Olanzapine + Risperidone + Quetiapine + Ziprasidone + Aripiprazole + Olanzapine + Risperidone + Quetiapine + Ziprasidone
Aripiprazole + Olanzapine + Risperidone + Quetiapine + Ziprasidone + Aripiprazole + Olanzapine + Risperidone + Quetiapine + Ziprasidone is a phase 3 stage product being developed by Pfizer for Schizophrenia and Schizoaffective Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00347425. Target conditions include Schizophrenia and Schizoaffective Disorder.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia and Schizoaffective Disorder were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00347425 | Phase 3 | Completed |
Competing Products
20 competing products in Schizophrenia and Schizoaffective Disorder